Trinity's haemostasis analyser gets US nod
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Destiny Max, Trinity Biotech's high-throughput haemostasis analyser. The Bray, Ireland firm immediately launched the device in the US, saying that this completes the rollout of the device in all major markets. The Destiny Max will be aimed towards university hospitals, high-throughput general hospitals, high-volume commercial laboratories and reference laboratories. Trinity estimates the worldwide high-throughput haemostasis market at $500m per annum. It CE marked the analyser in December 2008.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.